Non-attendance at secondary prevention clinics: The effect on lipid management

Scottish Medical Journal

Volumn 50, Issue 2, 2005, Pages 54-56

  McLeod, Andrew L ^c,d   Brooks, L ^a   Taylor, V ^b   Wylie, A ^a   Currie, P F ^a   Dewhurst, N G ^a  

^a PERTH ROYAL INFIRMARY   (United Kingdom)

^b Health Centre Dalkeith Midlothian   (United Kingdom)

^c NINEWELLS HOSPITAL   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Cholesterol; Coronary disease; Non attender; Secondary prevention

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG USE; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NURSE; OUTPATIENT CARE; PRIMARY MEDICAL CARE; QUANTITATIVE ANALYSIS; SECONDARY PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 21244505429     PISSN: 00369330     EISSN: None     Source Type: Journal    
DOI: 10.1177/003693300505000204     Document Type: Article

References (23)

1. Department of Health. National service framework for coronary heart disease. London: DoH, 2000.
2. McAlister FA, Lawson FME, Teo KK, Armstrong PW. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. Br Med J 2001;323:957-962.
3. Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. Br Med J 2003;326:84
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9
7. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
8. Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
9. Schwartz G, Olsson A, Ezekowitz M, Ganz P, Oliver M, Waters D et al. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes. The MIRACL Study: A Randomized Controlled Trial. JAMA. 2001;285:1711-1718
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
11. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM et al. Prospective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov 23;360(9346):1623-30
12. Sever PS Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.Lancet 2003;36:1149-58
13. Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. Br Med J 1998;317:1134-5.
14. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-572
15. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. Br Med J 2000;321:1322-5.
16. DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 2003;89:417-21
17. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program(CHAMP).AmJCardiol 2001;87:819-22
18. Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson Rr et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257-61
19. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001;357:1063-8
20. Stenestrand U; Wallentin L. Early Statin Treatment Following Acute Myocardial Infarction and 1-Year Survival. JAMA 2001;285:430-436.
21. Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F et al. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000;86:1293-8
22. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
23. Packham C, Pearson J, Robinson J, Gray D. Use of statins in general practices, 1996-8: cross sectional study. Br Med J 2000;320:1583-4.